This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Lunsumio (mosunetuzumab-axgb)
General Description:
Lunsumio (mosunetuzumab-axgb) is a bispecific antibody designed to bind both CD20 on B-cells and CD3 on T-cells. It is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
By engaging CD3-positive T-cells and CD20-positive B-cells, Lunsumio helps direct the body’s own immune system to identify and eliminate malignant B-cells, offering a targeted and effective therapeutic option for patients with heavily pretreated follicular lymphoma.
Lunsumio received U.S. FDA approval in December 2022 and European Medicines Agency (EMA) authorization in June 2023, marking a major advancement in the treatment of B-cell malignancies.
Disease Indications:
Lymphoma (Follicular Lymphoma – FL)
Manufacturer:
Genentech, Inc.
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• Single-dose vial × 1 mg/mL
• Single-dose vial × 30 mg/30 mL
Shipping:
Cold Chain Shipping
Certain biological medicines, including Lunsumio, are sensitive to heat, light, and handling. To preserve product stability and potency, Lunsumio is transported under strict cold chain conditions using specialized medical couriers equipped with temperature-controlled packaging and vehicles.
Although cold chain delivery may be costlier than standard shipping, it ensures that the medicine maintains its quality and therapeutic effectiveness throughout transit.
How to Access Lunsumio (mosunetuzumab-axgb) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Lunsumio (mosunetuzumab-axgb) is not yet approved or commercially available in India, MitoGENE can assist patients and physicians in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
